Nifedipine Plus Magnesium Sulfate Versus Magnesium Sulfate Alone for Tocolysis in Pregnant Women at 28 - 31 Weeks Gestation With Threatened Preterm Labor
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 264
- 试验地点
- 1
- 主要终点
- Number of women not delivered within 48 hours of starting tocolytic therapy.
研究概览
简要总结
Objective: This trial is designed to compare between the effectiveness of nifedipine plus magnesium sulfate (MgSO4) and MgSO4 alone for tocolysis in women with threatened preterm labor.
Patient Population: The population will include pregnant women at gestational age between 28 and 31 weeks who are 18 years old or older and have signs of threatened preterm labor.
Study Design: This is a single-center, prospective, randomized controlled clinical trial. A total of 264 women pregnant between 28 and 31 weeks having threatened preterm labor will be enrolled and randomized into two parallel treatment arms. Patients in the group A will receive nifedipine plus MgSO4, while patients in group B will MgSO4 only.
Treatment: All patients will be randomized on the day of enrollment. Patients with threatened preterm labor will receive the respective tocolysis in each group. All patients will receive corticosteroids for lung maturity according to the local protocol.
Primary outcome: Number of women not delivered within 48 hours of starting tocolytic therapy.
Secondary outcomes: perinatal mortality, a composite of adverse neonatal outcomes, birth weight, days on ventilation support, length of admission in neonatal intensive care, prolongation of pregnancy more than 7 days, delivery after 37 weeks of gestation, number of days till delivery, maternal mortality, maternal infection, and harm to mother from intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pregnant women with threatened preterm labor defined as 3 or more uterine contractions in 30 minutes confirmed by cardiotocography.
- •Gestational age from 28 week + 0 days to (inclusive) 31 weeks + 6 days.
- •Women with singleton or multiple pregnancy.
- •Women with preterm prelabor rupture of membranes (PROM) will be included if they have uterine contractions.
排除标准
- •Contraindications for the use of either drugs, such as cardiac disease, hypotension, myasthenia gravis, or renal impairment.
- •Contraindications for tocolysis, such as intrauterine demise, intrauterine infection, fetal distress, placental separation, or severe pre-eclampsia.
- •Cervical dilatation > 5 cm.
- •Cervical length > 30 mm by trans-vaginal ultrasound.
- •Cervical cerclage.
研究组 & 干预措施
A
Nifedipine + Magnesium sulfate
干预措施: Nifedipine 20 Mg (Drug)
A
Nifedipine + Magnesium sulfate
干预措施: Magnesium sulfate (Drug)
B
Magnesium Sulfate
干预措施: Magnesium sulfate (Drug)
结局指标
主要结局
Number of women not delivered within 48 hours of starting tocolytic therapy.
时间窗: 48 hours
postponing delivery for at least 48 hours to allow the time for corticosteroid administration for fatal lung maturity
次要结局
- Perinatal mortality(From starting treatment until 1 month of delivery)
- days on ventilation support(within 1 month of delivery)
- length of admission in neonatal intensive care(within 1 month of delivery)
- Delivery after 37 weeks of gestation.(after 37th week of delivery)
- A composite of adverse neonatal outcomes(within 1 month of delivery)
- Number of days till delivery(from starting the intervention until delivery)
- Harm to mother from interventions (side effects)(from starting treatment until 1 month after delivery)
- Prolongation of pregnancy more than 7 days(7 days after initiation of therapy)
- Maternal mortality rate(from starting treatment until 1 month after delivery)
- Maternal infection rate(from starting treatment until 1 month after delivery)
研究者
Karim Abdallah
Principal Investigator
Assiut University